Intellia Therapeutics said Sunday that the first 10 patients to receive a CRISPR-based treatment for hereditary angioedema, a genetic disease, saw their swelling attacks — the condition’s hallmark symptom — virtually eliminated for an average of 20 months and counting. The attacks were reduced by an average of 98%. One patient has remained attack-free...

You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up here. CHICAGO — It’s Sunday and the gorgeous June weather in Chicago has returned. But fear not, we’re inside writing about cancer drugs and research for you. Who remembers the car chase scene from the Blues Brothers...

CHICAGO — Comfort can be delivered to patients with advanced cancer virtually just as well as in person, according to a new study presented on Sunday at the American Society of Clinical Oncology annual meeting in Chicago. That’s welcome news to palliative care experts who have, in many cases, preferred the convenience and efficacy of telehealth sessions...

In patients with stage 3 lung cancer where a particular genetic mutation is present in the tumor, taking AstraZeneca’s cancer-fighting pill Tagrisso reduced the chance that disease would progress by 84%. “This will be practice changing as soon as this becomes available,” said David R. Spigel, chief scientific officer of the Sarah Cannon Research Institute...

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease. The makers of Enhertu, Daiichi Sankyo and AstraZeneca,...

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward. At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep,...